Larvol Delta - Afmed-Provides-Followup-Data-of-AFM24-plus-Atezolizumab-Showing-Durable-Responses-in-Heavily-Pretreated-NSCLC-EGFR-Wildtype-Patients-and-Positive-Initial-Data-from-the-NSCLC-EGFR-Mutant-Cohort

AFM24 - Affimed

https://www.globenewswire.com/news-release/2024/06/01/2891828/0/en/Affimed-Provides-Follow-up-Data-of-AFM24-plus-Atezolizumab-Showing-Durable-Responses-in-Heavily-Pretreated-NSCLC-EGFR-Wild-type-Patients-and-Positive-Initial-Data-from-the-NSCLC-EG.html

Jun 1, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next